Li-Fraumeni and Li-Fraumeni - Like syndrome among children diagnosed with pediatric cancer in Southern Brazil

Cancer

Volumn 119, Issue 24, 2013, Pages 4341-4349

  Giacomazzi, Juliana ^a,b   Selistre, Simone G ^a,b   Rossi, Cristina ^a,b   Alemar, Barbara ^a,b   Santos Silva, Patricia ^a,b   Pereira, Fernando S ^a,b   Netto, Cristina B ^a   Cossio, Silvia L ^a,b   Roth, Daniela E ^a   Brunetto, Algemir L ^a   Zagonel Oliveira, Marcelo ^b   Martel Planche, Ghyslaine ^c   Goldim, Jose R ^a   Hainaut, Pierre ^d   Camey, Suzi A ^b   Ashton Prolla, Patricia ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

childhood cancer; Li Fraumeni syndrome; Li Fraumeni like syndrome; TP53 mutations; TP53 p.R337H mutation

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; ARTICLE; BRAZIL; CHILD; CHILDHOOD CANCER; CHOROID PLEXUS CARCINOMA; CHOROID PLEXUS TUMOR; CONTROLLED STUDY; DNA BINDING; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE LOCUS; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC SCREENING; HAPLOTYPE; HETEROZYGOSITY LOSS; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; LI FRAUMENI LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MUTANT; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE;

CHILDHOOD CANCER; LI-FRAUMENI SYNDROME; LI-FRAUMENI-LIKE SYNDROME; TP53 MUTATIONS; TP53 P.R337H MUTATION;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; BRAZIL; CARCINOMA; CHILD; CHILD, PRESCHOOL; CHOROID PLEXUS NEOPLASMS; FEMALE; GENE REARRANGEMENT; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; INFANT; LI-FRAUMENI SYNDROME; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84889884686     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28346     Document Type: Article

References (41)

1. National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER). Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. seer.cancer.gov/publications/childhood/. Accessed July 1, 2012.
2. International Agency for Research on Cancer. Automated Childhood Cancer Information System (ACCIS). accis.iarc.fr/results/index.php Accessed July 1, 2012.
3. Parkin DM, Stiller CA, Draper GJ, et al. The international incidence of childhood cancer. Int J Cancer. 1988; 42: 511-520.
4. Parkin DM,. Epidemiology of cancer: global patterns and trends. Toxicol Lett. 1998; 102-103: 227-234.
5. Instituto Nacional do Cancer. Estimativa 2012. www.inca.gov.br/ estimativa/2012/. Accessed July 1, 2012.
6. Monsalve J, Kapur J, Malkin D, et al. Imaging of cancer predisposition syndromes in children. Radiographics. 2011; 31: 263-280.
7. Li FP, Fraumeni JF,. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst. 1969; 43: 1365-1373.
8. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250: 1233-1238.
9. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998; 90: 606-611.
10. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001; 20: 4621-4628.
11. Lalloo F, Varley J, Moran A, et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer. 2006; 42: 1143-1150.
12. Li FP, Fraumeni JF,. Prospective study of a family cancer syndrome. JAMA. 1982; 247: 2692-2694.
13. Li FP, Fraumeni JF, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988; 48: 5358-5362.
14. Eeles RA,. Germline mutations in the TP53 gene. Cancer Surv. 1995; 25: 101-124.
15. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994; 54: 1298-1304.
16. Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 2001; 38: 43-47.
17. Chompret A, Brugieres L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000; 82: 1932-1937.
18. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol. 2009; 27: e108-e109; author reply e110.
19. Nagy R, Sweet K, Eng C,. Highly penetrant hereditary cancer syndromes. Oncogene. 2004; 23: 6445-6470.
20. Varley J,. TP53, hChk2, and the Li-Fraumeni syndrome. Methods Mol Biol. 2003; 222: 117-129.
21. Strong LC,. General keynote: hereditary cancer: lessons from Li-Fraumeni syndrome. Gynecol Oncol. 2003; 88 (1 pt 2): S4-S7; discussion S11-S13.
22. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009; 27: 1250-1256.
23. Evans DG, Birch JM, Thorneycroft M, et al. Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome. J Med Genet. 2002; 39: 941-944.
24. Varley JM, McGown G, Thorncroft M, et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res. 1997; 57: 3245-3252.
25. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A. 2001; 98: 9330-9335.
26. Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab. 2001; 86: 4970-4973.
27. Figueiredo BC, Sandrini R, Zambetti GP, et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet. 2006; 43: 91-96.
28. Achatz MI, Olivier M, Le Calvez F, et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett. 2007; 245: 96-102.
29. Palmero EI, Schuler-Faccini L, Caleffi M, et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett. 2008; 261: 21-25.
30. Custodio G, Taques GR, Figueiredo BC, et al. Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil. PLoS One. 2011; 6: e18015.
31. Assumpcao JG, Seidinger AL, Mastellaro MJ, et al. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer. 2008; 8: 357.
32. Seidinger AL, Mastellaro MJ, Paschoal Fortes F, et al. Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil. Cancer. 2011; 117: 2228-2235.
33. Waldmann J, Patsalis N, Fendrich V, et al. Clinical impact of TP53 alterations in adrenocortical carcinomas. Langenbecks Arch Surg. 2012; 397: 209-216.
34. Herrmann LJ, Heinze B, Fassnacht M, et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2012; 97: E476-E485.
35. Garritano S, Gemignani F, Palmero EI, et al. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat. 2010; 31: 143-150.
36. Piovezan GC,. Prevalencia do alelo R337H no Estado do Parana [master's thesis]. Curitiba, Parana, Brazil: Federal University of Parana; 2006.
37. International Agency for Research on Cancer. Detection of TP53 Mutations by Direct Sequencing. p53.iarc.fr/download/tp53-directsequencing-iarc.pdf. Accessed July 1, 2012.
38. Frebourg T, Abel A, Bonaiti-Pellie C, et al. Li-Fraumeni syndrome: update, new data and guidelines for clinical management. Bull Cancer. 2001; 88: 581-587.
39. Bougeard G, Sesboue R, Baert-Desurmont S, et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet. 2008; 45: 535-538.
40. Weinberg RA,. Tumor suppressor genes. Science. 1991; 254: 1138-1146.
41. Ponder BA,. Cancer genetics. Nature. 2001; 411: 336-341.